<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01355523</url>
  </required_header>
  <id_info>
    <org_study_id>MVH-03</org_study_id>
    <secondary_id>2010-022460-12</secondary_id>
    <secondary_id>2007-58-0015/HEH.750.89-12</secondary_id>
    <secondary_id>H-4-2011-007</secondary_id>
    <nct_id>NCT01355523</nct_id>
  </id_info>
  <brief_title>The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients</brief_title>
  <acronym>MELODY</acronym>
  <official_title>The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melissa Voigt Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of 6 mg melatonin daily for 1 week
      preoperatively to 12 weeks postoperatively on depressive symptoms, anxiety, cognitive
      function and sleep disturbances in breast cancer patients. Furthermore the investigators will
      examine whether a specific clock-gene (HPER3) is correlated with an increased risk of
      depression, sleep disturbances or cognitive dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 1.4 million women are diagnosed with breast cancer every year. Breast cancer is the
      most common malignancy among women worldwide constituting about 1/5 of all cancer types.
      Breast cancer diagnosis and treatment, and the months following primary therapy are stressful
      times for most women. Aside from the actual &quot;cancer threat&quot; many women experience various
      degrees of depression, anxiety, sleep disturbances and memory/concentration problems
      (cognitive dysfunction). Naturally these factors influence the quality of life but also
      contribute to morbidity and mortality.

      Melatonin is a regulatory circadian hormone having, among others, hypnotic, sedative,
      anxiolytic and possibly anti-depressive effects. It has very low toxicity and very few
      adverse effects.

      The purpose of this project is to test melatonin (6 mg daily for 1 week preoperatively to 12
      weeks postoperatively) on breast cancer patients and hopefully hereby be able to prevent
      depression, anxiety, sleep disturbances and cognitive dysfunction. On an overall perspective
      this will hopefully contribute to improving the quality of life for these patients and extend
      their lifetime. Furthermore the investigators will be examining whether a specific gene
      called a clock-gene (HPER3) is correlated with an increased risk of depression, sleep
      disturbances or cognitive dysfunction. If this is the case it could become possible to
      identify women with an increased risk and provide prophylactic treatment for those with a
      risk of developing a depression, sleep disturbances or cognitive disturbances.

      Sample size calculations were based on our primary outcome parameter. Using a conservative
      estimate for the incidence of depression, the investigators expect to find a reduction from
      30% to 15% with melatonin treatment. Sample size is sufficient to include our secondary and
      tertiary outcome parameters as well. The sample size calculations were calculated with a
      power of 80%, a type I error of 5% and a type II error of 20%.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inclusion rate not as expected. Not financially possible to involve other centres.
  </why_stopped>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Depression Inventory (MDI)- Depression at One Point in the Study</measure>
    <time_frame>Depression at one point in the study (not including baseline) out of 4 measurements at app. day 21, day 35, day 63 and day 91 of the study.</time_frame>
    <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Diagnostic scale using the ICD-10 algorithm:
Mild depression: 2 core symptoms and 2 other symptoms Moderate depression: 2 core symptoms and 4 other symptoms Severe depression: 3 core symptoms and 5 other symptoms
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Per Protocol - Depression at One Point in the Study Period</measure>
    <time_frame>Per protocol - depression at one point in the study period (not baseline)</time_frame>
    <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 This analysis includes only patients who have taken study medication as planned.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intention to Treat (Underestimate) - Depression at One Point in the Study Period</measure>
    <time_frame>Intention to treat (underestimate) - depression at one point in the study period (not baseline)</time_frame>
    <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as &quot;NO&quot; depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intention to Treat (Overestimate) - Depression at One Point in the Study Period</measure>
    <time_frame>Intention to treat (overestimate) - depression at one point in the study period (not baseline)</time_frame>
    <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as &quot;YES&quot; for depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Anxiety - Immediate Postoperative Period</measure>
    <time_frame>Daily - from inclusion till 8 days postoperatively</time_frame>
    <description>Anxiety measured by VAS (visual analog scale). A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Anxiety - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>Anxiety measured by VAS (visual analog scale). Completed every 14th day. A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Immediate Postoperative Period</measure>
    <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
    <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Fatigue - Immediate Postoperative Period</measure>
    <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
    <description>Fatigue on a Visual Analog Scale - filled out daily. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Fatigue - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>Fatigue on a Visual Analog Scale - filled out every 14th day. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for Data on General Well-being - Immediate Postoperative Period</measure>
    <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
    <description>General well-being on a Visual Analog Scale - filled out daily. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on General Well-being - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>General well-being on a Visual Analog Scale - filled out every 14th day. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Pain - Immediate Postoperative Period</measure>
    <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
    <description>Pain on a Visual Analog Scale - filled out daily. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Pain - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>Pain on a Visual Analog Scale - filled out every 14th day. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Immediate Postoperative Period</measure>
    <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
    <description>Subjective sleep score on Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Long-term Postoperative Period</measure>
    <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
    <description>Subjective sleep on a Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Architecture</measure>
    <time_frame>From inclusion till 14 days postoperatively</time_frame>
    <description>Actigraphy (total minutes asleep, sleep effectiveness, sleep latency, awakenings). A wrist actigraph will be worn from inclusion till 14 days postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HPER3 Genotype</measure>
    <time_frame>At inclusion = day-7</time_frame>
    <description>A blood sample will be taken at inclusion and analysed for HPER3 genotype (4/4, 4/5, 5/5) and this will be investigated for a correlation with sleep, cognitive function and depressive symptoms 7 patients did not give blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 2 Weeks Postoperatively.</measure>
    <time_frame>App. 2 weeks postoperatively</time_frame>
    <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 10 Weeks Postoperatively</measure>
    <time_frame>App. 10 weeks postoperatively</time_frame>
    <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 mg oral melatonin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 mg oral placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin (N-acetyl-5-methoxytryptamine)</intervention_name>
    <description>6 mg oral melatonin daily 1 hour before bedtime</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Melatonin</other_name>
    <other_name>N-acetyl-5-methoxytryptamin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 mg oral placebo daily 1 hour before bedtime</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women, age 30-75, with breast cancer who are admitted for a lumpectomy or mastectomy
             at Herlev Hospital

          -  ASA score I-III

          -  No sign of depression measured my Major Depression Inventory (MDI)

          -  Not pregnant

        Exclusion Criteria:

          -  Neoadjuvant chemotherapy

          -  Treatment with SSRI, Warfarin or other anticoagulants (except 75 mg ASA daily), MAO
             inhibitors or calcium blockers

          -  Rotor or Dubin-Johnson syndrome

          -  Epilepsy

          -  Known allergic reaction to melatonin

          -  Known and treated sleep apnea

          -  Diabetes Mellitus - insulin treated

          -  Ongoing or previous medically treated depression or bipolar disorder

          -  Known autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis
             (RA), and sclerose

          -  Incompensated liver cirrhosis

          -  Severe kidney disease

          -  Previous or current cancer

          -  Known medically treated sleep-disorder (insomnia, restless legs etc)

          -  Shift-work and night-work

          -  Daily alcohol intake of more than 5 units

          -  Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics
             (including all sleeping pills)

          -  Predicted bad compliance

          -  Pregnant or breast-feeding

          -  Pre-operative Mini Mental State Evaluation (MMSE) score less than 24
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa V Hansen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.cpodenmark.dk</url>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2011</study_first_submitted>
  <study_first_submitted_qc>May 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2011</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>April 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 6, 2014</results_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Melissa Voigt Hansen</investigator_full_name>
    <investigator_title>M.D., ph-D student</investigator_title>
  </responsible_party>
  <keyword>Breast cancer surgery</keyword>
  <keyword>Melatonin</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Sleep disturbances</keyword>
  <keyword>Cognitive function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The recruitment period was from July 2011 till December 2012. The location was The Department of Breast Surgery - Herlev Hospital, Copenhagen - Denmark.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Melatonin</title>
          <description>6 mg oral melatonin daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>6 mg oral placebo daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Melatonin</title>
          <description>6 mg oral melatonin daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>6 mg oral placebo daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.50" spread="10.69"/>
                    <measurement group_id="B2" value="58.23" spread="11.36"/>
                    <measurement group_id="B3" value="56.30" spread="11.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of surgery</title>
          <description>SN: sentinel node</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mastectomy + axillary dissection +/- SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mastectomy + SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumpectomy + axillary dissection +/- SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumpectomy + SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumpectomy converted to mastectomy + SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral lumpectomy + axillary dissection + SN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgery duration</title>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92" lower_limit="74.5" upper_limit="125"/>
                    <measurement group_id="B2" value="125" lower_limit="104.5" upper_limit="156.5"/>
                    <measurement group_id="B3" value="110" lower_limit="85" upper_limit="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anaesthesia duration</title>
          <units>Minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="155" lower_limit="130" upper_limit="187"/>
                    <measurement group_id="B2" value="190" lower_limit="155" upper_limit="225"/>
                    <measurement group_id="B3" value="171" lower_limit="139.25" upper_limit="196.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oncological treatment</title>
          <description>Only registered as which oncological treatment (if any at all) the patients received during their participation in the MELODY trial</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy + radiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radiation x 1 only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drop-out before chemo/radiation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anti-hormone therapy</title>
          <description>Only registered as which anti-hormone therapy (if any at all) the patients received during their participation in the MELODY trial</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drop-out before anti-hormone therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDI - Major Depression Inventory</title>
          <description>The MDI is a self-rating scale including 12 questions and has been validated in a Danish population. The MDI assesses information on depressive symptoms that have been present continuously during the previous 2 weeks. The individual items are measured on a 6-point Likert scale, ranging from 0 to 5, with graduations depending on the extent of the symptom the previous 14 days. Accordingly, the theoretical score ranges from 0 to 50.</description>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" lower_limit="4" upper_limit="12.5"/>
                    <measurement group_id="B2" value="7" lower_limit="4.5" upper_limit="10"/>
                    <measurement group_id="B3" value="7" lower_limit="4" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menopausal status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Premenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postmenopausal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Major Depression Inventory (MDI)- Depression at One Point in the Study</title>
        <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Diagnostic scale using the ICD-10 algorithm:
Mild depression: 2 core symptoms and 2 other symptoms Moderate depression: 2 core symptoms and 4 other symptoms Severe depression: 3 core symptoms and 5 other symptoms
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50</description>
        <time_frame>Depression at one point in the study (not including baseline) out of 4 measurements at app. day 21, day 35, day 63 and day 91 of the study.</time_frame>
        <population>Includes all patients who have completed at least one other MDI than baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Major Depression Inventory (MDI)- Depression at One Point in the Study</title>
          <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Diagnostic scale using the ICD-10 algorithm:
Mild depression: 2 core symptoms and 2 other symptoms Moderate depression: 2 core symptoms and 4 other symptoms Severe depression: 3 core symptoms and 5 other symptoms
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50</description>
          <population>Includes all patients who have completed at least one other MDI than baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Number need to treat</param_type>
            <param_value>2.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.703</ci_lower_limit>
            <ci_upper_limit>11.024</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Relative Risk</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.076</ci_lower_limit>
            <ci_upper_limit>0.797</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Per Protocol - Depression at One Point in the Study Period</title>
        <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 This analysis includes only patients who have taken study medication as planned.</description>
        <time_frame>Per protocol - depression at one point in the study period (not baseline)</time_frame>
        <population>Includes only patients who have taken the study medication as planned</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Per Protocol - Depression at One Point in the Study Period</title>
          <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 This analysis includes only patients who have taken study medication as planned.</description>
          <population>Includes only patients who have taken the study medication as planned</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.125</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intention to Treat (Underestimate) - Depression at One Point in the Study Period</title>
        <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as NO depression.</description>
        <time_frame>Intention to treat (underestimate) - depression at one point in the study period (not baseline)</time_frame>
        <population>All missing MDI data have been analyzed as &quot;NO&quot; depression.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Intention to Treat (Underestimate) - Depression at One Point in the Study Period</title>
          <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as NO depression.</description>
          <population>All missing MDI data have been analyzed as &quot;NO&quot; depression.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.460</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Intention to Treat (Overestimate) - Depression at One Point in the Study Period</title>
        <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as YES for depression.</description>
        <time_frame>Intention to treat (overestimate) - depression at one point in the study period (not baseline)</time_frame>
        <population>All missing data have been analyzed as &quot;YES&quot; depression.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Intention to Treat (Overestimate) - Depression at One Point in the Study Period</title>
          <description>MDI is a self-rating depression scale with 12 questions. MDI has previously been investigated in a Danish population. On a six-point Likert scale, the items measure how much time the symptoms have been present during the last 14 days. MDI is scored according to specific guidelines and can be used either as a rating scale or diagnostic instrument.
For inclusion we used the diagnostic instrument (depression was an exclusion criteria) and for all other MDI measurements we used the rating scale.
Rating scale:
No depression - score from 0-20 Mild depression - score from 21-25 Moderate depression - score from 26-30 Severe depression - score from 31-50 For this analysis all missing MDI data have been analyzed as YES for depression.</description>
          <population>All missing data have been analyzed as &quot;YES&quot; depression.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>NO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>YES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Anxiety - Immediate Postoperative Period</title>
        <description>Anxiety measured by VAS (visual analog scale). A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily - from inclusion till 8 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Anxiety - Immediate Postoperative Period</title>
          <description>Anxiety measured by VAS (visual analog scale). A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <units>mm*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="44" upper_limit="160"/>
                    <measurement group_id="O2" value="140" lower_limit="46" upper_limit="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Anxiety - Long-term Postoperative Period</title>
        <description>Anxiety measured by VAS (visual analog scale). Completed every 14th day. A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <population>Patients were only included in the analysis if they had completed VAS on anxiety in the long-term postoperative period. Single missing data were filled out using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Anxiety - Long-term Postoperative Period</title>
          <description>Anxiety measured by VAS (visual analog scale). Completed every 14th day. A subjective feeling of anxiety was registered on a VAS going from &quot;no anxiety&quot;, equivalent to 0mm to &quot;worst possible anxiety&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <population>Patients were only included in the analysis if they had completed VAS on anxiety in the long-term postoperative period. Single missing data were filled out using last observation carried forward.</population>
          <units>mm*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="4" upper_limit="31"/>
                    <measurement group_id="O2" value="19" lower_limit="8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.351</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Immediate Postoperative Period</title>
        <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Immediate Postoperative Period</title>
          <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <units>Units on KSS*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="26" upper_limit="48"/>
                    <measurement group_id="O2" value="39" lower_limit="31" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.446</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Long-term Postoperative Period</title>
        <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for Data on Sleepiness (KSS) - Long-term Postoperative Period</title>
          <description>Sleepiness measured by Karolinska Sleepiness Scale. KSS is a 9-point scale from 1 (very awake) to 9 (very sleepy) where a score of 7 or more reflects pathological sleepiness.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <units>Units on KSS*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="14" lower_limit="12" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.122</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Fatigue - Immediate Postoperative Period</title>
        <description>Fatigue on a Visual Analog Scale - filled out daily. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Fatigue - Immediate Postoperative Period</title>
          <description>Fatigue on a Visual Analog Scale - filled out daily. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <units>mm*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="307" lower_limit="93" upper_limit="399"/>
                    <measurement group_id="O2" value="300" lower_limit="146" upper_limit="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.907</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Fatigue - Long-term Postoperative Period</title>
        <description>Fatigue on a Visual Analog Scale - filled out every 14th day. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Fatigue - Long-term Postoperative Period</title>
          <description>Fatigue on a Visual Analog Scale - filled out every 14th day. A subjective feeling of fatigue was registered on a VAS going from &quot;no fatigue&quot;, equivalent to 0mm to &quot;worst possible fatigue&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <units>mm*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" lower_limit="58" upper_limit="147"/>
                    <measurement group_id="O2" value="88" lower_limit="41" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.555</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for Data on General Well-being - Immediate Postoperative Period</title>
        <description>General well-being on a Visual Analog Scale - filled out daily. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
        <population>Patients were only included in the analysis if they had completed daily VAS on anxiety for at least 8 days postoperatively. Single missing data were filled out using last observation carried forward.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for Data on General Well-being - Immediate Postoperative Period</title>
          <description>General well-being on a Visual Analog Scale - filled out daily. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <population>Patients were only included in the analysis if they had completed daily VAS on anxiety for at least 8 days postoperatively. Single missing data were filled out using last observation carried forward.</population>
          <units>mm*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282" lower_limit="211" upper_limit="436"/>
                    <measurement group_id="O2" value="372" lower_limit="180" upper_limit="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.930</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on General Well-being - Long-term Postoperative Period</title>
        <description>General well-being on a Visual Analog Scale - filled out every 14th day. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on General Well-being - Long-term Postoperative Period</title>
          <description>General well-being on a Visual Analog Scale - filled out every 14th day. A subjective feeling of general well-being was registered on a VAS going from &quot;very high well-being&quot;, equivalent to 0mm to &quot;very low well-being&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <units>mm*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" spread="141" lower_limit="52" upper_limit="141"/>
                    <measurement group_id="O2" value="89" spread="44" lower_limit="44" upper_limit="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.386</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Pain - Immediate Postoperative Period</title>
        <description>Pain on a Visual Analog Scale - filled out daily. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Pain - Immediate Postoperative Period</title>
          <description>Pain on a Visual Analog Scale - filled out daily. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <units>mm*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" lower_limit="45" upper_limit="181"/>
                    <measurement group_id="O2" value="130" lower_limit="46" upper_limit="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.241</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Pain - Long-term Postoperative Period</title>
        <description>Pain on a Visual Analog Scale - filled out every 14th day. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Pain - Long-term Postoperative Period</title>
          <description>Pain on a Visual Analog Scale - filled out every 14th day. A subjective feeling of pain was registered on a VAS going from &quot;no pain&quot;, equivalent to 0mm to &quot;worst possible pain&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <units>mm*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="2" upper_limit="48"/>
                    <measurement group_id="O2" value="22" lower_limit="8" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.339</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Immediate Postoperative Period</title>
        <description>Subjective sleep score on Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
        <time_frame>Daily from inclusion till 8 days postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Immediate Postoperative Period</title>
          <description>Subjective sleep score on Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed daily VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness for at least 8 days postoperatively.
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 2 %</description>
          <units>mm*day</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279" lower_limit="203" upper_limit="466"/>
                    <measurement group_id="O2" value="355" lower_limit="194" upper_limit="441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.578</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Long-term Postoperative Period</title>
        <description>Subjective sleep on a Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
        <time_frame>App. 14 days postoperatively till 10 weeks postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) for VAS Data on Sleep Quality - Long-term Postoperative Period</title>
          <description>Subjective sleep on a Visual Analog Scale. Subjective sleep quality was registered on a VAS going from &quot;best possible sleep&quot;, equivalent to 0mm to &quot;worst possible sleep&quot;, equivalent to 100mm.
Patients were only included in the analysis if they had completed VAS on anxiety, sleep quality, general well-being, fatigue, pain and sleepiness in the long-term postoperative period (every 14th day).
Single missing data were filled out using last observation carried forward (LOCF). % of cases filled out by LOCF &lt; 1 %</description>
          <units>mm*2 weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101" lower_limit="51" upper_limit="148"/>
                    <measurement group_id="O2" value="116" lower_limit="51" upper_limit="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Architecture</title>
        <description>Actigraphy (total minutes asleep, sleep effectiveness, sleep latency, awakenings). A wrist actigraph will be worn from inclusion till 14 days postoperatively.</description>
        <time_frame>From inclusion till 14 days postoperatively</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HPER3 Genotype</title>
        <description>A blood sample will be taken at inclusion and analysed for HPER3 genotype (4/4, 4/5, 5/5) and this will be investigated for a correlation with sleep, cognitive function and depressive symptoms 7 patients did not give blood samples</description>
        <time_frame>At inclusion = day-7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>HPER3 Genotype</title>
          <description>A blood sample will be taken at inclusion and analysed for HPER3 genotype (4/4, 4/5, 5/5) and this will be investigated for a correlation with sleep, cognitive function and depressive symptoms 7 patients did not give blood samples</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4/4 genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4/5 genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5/5 genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 2 Weeks Postoperatively.</title>
        <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
        <time_frame>App. 2 weeks postoperatively</time_frame>
        <population>Analysis includes only patients who completed all parts of the neuropsychological test battery at baseline and 2 weeks postoperatively.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 2 Weeks Postoperatively.</title>
          <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
          <population>Analysis includes only patients who completed all parts of the neuropsychological test battery at baseline and 2 weeks postoperatively.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 10 Weeks Postoperatively</title>
        <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
        <time_frame>App. 10 weeks postoperatively</time_frame>
        <population>Analysis includes only patients who completed all parts of the neuropsychological test battery at baseline and 10 weeks postoperatively.</population>
        <group_list>
          <group group_id="O1">
            <title>Melatonin</title>
            <description>6 mg oral melatonin daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>6 mg oral placebo daily</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Postoperative Cognitive Dysfunction (POCD) App. 10 Weeks Postoperatively</title>
          <description>Calculations for POCD were based on normative data from 133 females aged 40-60 years. We evaluated changes from the preoperative baseline to the 2 postoperative test sessions. In controls we calculated mean and standard deviations (SD) of these differences. The mean change in this group may be taken as estimated learning effects. For the individual patients, we compared baseline scores with the 2- and 12-week postoperative test results, subtracted the average learning effect from the changes and divided the result by the SD of the control group to obtain a Z score for the 7 individual test outcomes. A large positive Z score indicated deterioration in cognitive function from baseline in patients. We defined a composite Z score as the sum of the 7 Z scores and normalized this using the SD for that sum in the controls. POCD was defined as a combined Z score &gt;1.96 or a Z score &gt;1.96 in at least 2 of the 7 subtests.
Units of measure = % of patients with YES to POCD</description>
          <population>Analysis includes only patients who completed all parts of the neuropsychological test battery at baseline and 10 weeks postoperatively.</population>
          <units>Percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From inclusion (app. 1 week preoperatively) till the final visit (app. 10 weeks postoperatively)</time_frame>
      <desc>Only includes patients who have at least taken 1 dose of the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Melatonin</title>
          <description>6 mg oral melatonin daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>6 mg oral placebo daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Reflux</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Obstipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diffuse pain in the lower abdomen</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Difficulty falling asleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>More awakenings at night</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Itch (arms)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia (mouth region, arms/legs)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Memory problems</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Breathing difficulties</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flushing/sweating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Premature termination (54/260). Only included about 8% (54/703) of the patients assessed for eligibility.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>MD Melissa Voigt Hansen</name_or_title>
      <organization>Herlev Hospital, Department of Surgery</organization>
      <phone>+45 20661119</phone>
      <email>melissa.voigt.hansen@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

